van Horn, Noel http://orcid.org/0000-0001-5764-1982
Kniep, Helge
Broocks, Gabriel
Meyer, Lukas
Flottmann, Fabian
Bechstein, Matthias
Götz, Julia
Thomalla, Götz
Bendszus, Martin
Bonekamp, Susanne
Pfaff, Johannes Alex Rolf
Dellani, Paulo Roberto
Fiehler, Jens
Hanning, Uta
Funding for this research was provided by:
Horizon 2020 (754640)
Projekt DEAL
Article History
Received: 16 September 2020
Accepted: 14 December 2020
First Online: 27 January 2021
Compliance with ethical guidelines
:
: G. Thomalla: consulting fees from Acandis, grant support and lecture fees from Bayer, lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, and consulting fees and lecture fees from Stryker. Grants from Bundesministerium für Wirtschaft und Energie (BMWi), Deutsche Forschungsgemeinschaft (DFG), European Union (EU), German Innovation Fund, Corona Foundation. J.A.R. Pfaff: personal fees from Stryker, outside the submitted work. J. Fiehler: consultant for Acandis, Boehringer Ingelheim, Codman, Microvention, Sequent, Stryker. Speaker for Bayer Healthcare, Bracco, Covidien/ev3, Penumbra, Philips, Siemens. Grants from Bundesministeriums für Wirtschaft und Energie (BMWi), Bundesministerium für Bildung und Forschung (BMBF), Deutsche Forschungsgemeinschaft (DFG), European Union (EU), Covidien, Stryker (THRILL study), Microvention (ERASER study), Philips. N. van Horn, H. Kniep, G. Broocks, L. Meyer, F. Flottmann, M. Bechstein, J. Götz, M. Bendszus, S. Bonekamp, P.R. Dellani, and U. Hanning declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. This retrospective study was approved by the leading ethics committee of the medical faculty of the University of Heidelberg (S-248/2016).